BRPI0919876A8 - Composto, composição farmacêutica, uso de um composto, e, método para intensificar a qualidade do sono, para tratar insônia, e para tratar ou controlar obesidade em um paciente mamífero que necessita do mesmo. - Google Patents
Composto, composição farmacêutica, uso de um composto, e, método para intensificar a qualidade do sono, para tratar insônia, e para tratar ou controlar obesidade em um paciente mamífero que necessita do mesmo.Info
- Publication number
- BRPI0919876A8 BRPI0919876A8 BRPI0919876A BRPI0919876A BRPI0919876A8 BR PI0919876 A8 BRPI0919876 A8 BR PI0919876A8 BR PI0919876 A BRPI0919876 A BR PI0919876A BR PI0919876 A BRPI0919876 A BR PI0919876A BR PI0919876 A8 BRPI0919876 A8 BR PI0919876A8
- Authority
- BR
- Brazil
- Prior art keywords
- compound
- treatment
- pharmaceutical composition
- need
- mammalian patient
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 6
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 3
- 208000008589 Obesity Diseases 0.000 title 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 title 1
- 230000002708 enhancing effect Effects 0.000 title 1
- 206010022437 insomnia Diseases 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- 235000020824 obesity Nutrition 0.000 title 1
- 108050000742 Orexin Receptor Proteins 0.000 abstract 2
- 102000008834 Orexin receptor Human genes 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 230000002265 prevention Effects 0.000 abstract 2
- 208000012902 Nervous system disease Diseases 0.000 abstract 1
- 208000025966 Neurological disease Diseases 0.000 abstract 1
- 229940123730 Orexin receptor antagonist Drugs 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- VFQXVTODMYMSMJ-UHFFFAOYSA-N isonicotinamide Chemical class NC(=O)C1=CC=NC=C1 VFQXVTODMYMSMJ-UHFFFAOYSA-N 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000000926 neurological effect Effects 0.000 abstract 1
- 208000020016 psychiatric disease Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Obesity (AREA)
- Epidemiology (AREA)
- Anesthesiology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US19778908P | 2008-10-30 | 2008-10-30 | |
| US18057409P | 2009-05-22 | 2009-05-22 | |
| PCT/US2009/061987 WO2010051236A1 (en) | 2008-10-30 | 2009-10-26 | Isonicotinamide orexin receptor antagonists |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BRPI0919876A2 BRPI0919876A2 (pt) | 2015-08-18 |
| BRPI0919876A8 true BRPI0919876A8 (pt) | 2016-02-10 |
Family
ID=41348271
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0919876A BRPI0919876A8 (pt) | 2008-10-30 | 2009-10-26 | Composto, composição farmacêutica, uso de um composto, e, método para intensificar a qualidade do sono, para tratar insônia, e para tratar ou controlar obesidade em um paciente mamífero que necessita do mesmo. |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US8592457B2 (OSRAM) |
| EP (1) | EP2350010B1 (OSRAM) |
| JP (1) | JP5635991B2 (OSRAM) |
| KR (1) | KR101320245B1 (OSRAM) |
| CN (1) | CN102272103B (OSRAM) |
| AU (1) | AU2009308980B2 (OSRAM) |
| BR (1) | BRPI0919876A8 (OSRAM) |
| CA (1) | CA2741644C (OSRAM) |
| CL (1) | CL2011000976A1 (OSRAM) |
| CO (1) | CO6361994A2 (OSRAM) |
| CR (1) | CR20110228A (OSRAM) |
| DO (1) | DOP2011000120A (OSRAM) |
| EA (1) | EA201170624A1 (OSRAM) |
| EC (1) | ECSP11011019A (OSRAM) |
| IL (1) | IL212436A0 (OSRAM) |
| MA (1) | MA32804B1 (OSRAM) |
| MX (1) | MX2011004551A (OSRAM) |
| NI (1) | NI201100084A (OSRAM) |
| NZ (1) | NZ592544A (OSRAM) |
| PE (1) | PE20110852A1 (OSRAM) |
| TN (1) | TN2011000171A1 (OSRAM) |
| WO (1) | WO2010051236A1 (OSRAM) |
| ZA (1) | ZA201103156B (OSRAM) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009020642A1 (en) | 2007-08-09 | 2009-02-12 | Merck & Co., Inc. | Pyridine carboxamide orexin receptor antagonists |
| AR072899A1 (es) | 2008-08-07 | 2010-09-29 | Merck Sharp & Dohme | Derivados de terpiridina-carboxamida antagonistas de receptores de orexina, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento del insomnio y la obesidad. |
| US8703770B2 (en) | 2008-10-30 | 2014-04-22 | Merck Sharp & Dohme Corp. | Pyridazine carboxamide orexin receptor antagonists |
| US8399494B2 (en) | 2008-10-30 | 2013-03-19 | Merck Sharp & Dohme Corp. | 2,5-disubstituted phenyl carboxamide orexin receptor antagonists |
| US8680275B2 (en) | 2009-10-23 | 2014-03-25 | Janssen Pharmaceutica Nv | Fused heterocyclic compounds as orexin receptor modulators |
| US9062044B2 (en) | 2009-10-23 | 2015-06-23 | Janssen Pharmaceutica Nv | Disubstituted octahydropyrrolo[3,4-c]pyrroles as orexin receptor modulators |
| KR101859409B1 (ko) | 2009-10-23 | 2018-05-18 | 얀센 파마슈티카 엔.브이. | 오렉신 수용체 조절제로서의 이치환된 옥타하이드로피롤로［3,4-ｃ］피롤 |
| ES2541531T3 (es) * | 2011-02-18 | 2015-07-21 | Actelion Pharmaceuticals Ltd. | Nuevos derivados de pirazol e imidazol útiles como antagonistas de orexina |
| US9586962B2 (en) | 2011-04-20 | 2017-03-07 | Janssen Pharmaceutica Nv | Disubstituted octahydropyrrolo [3,4-C] pyrroles as orexin receptor modulators |
| AR088352A1 (es) * | 2011-10-19 | 2014-05-28 | Merck Sharp & Dohme | Antagonistas del receptor de 2-piridiloxi-4-nitrilo orexina |
| US9440982B2 (en) | 2012-02-07 | 2016-09-13 | Eolas Therapeutics, Inc. | Substituted prolines/piperidines as orexin receptor antagonists |
| NZ628491A (en) | 2012-02-07 | 2016-06-24 | Eolas Therapeutics Inc | Substituted prolines / piperidines as orexin receptor antagonists |
| ME02606B (me) | 2012-06-15 | 2017-06-20 | Taisho Pharmaceutical Co Ltd | Jedinjenja 1,3 - oksazolidina ili 1,3- oksazinana kao antagonisti oreksinskog receptora |
| KR20150023390A (ko) * | 2012-06-15 | 2015-03-05 | 다이쇼 세이야꾸 가부시끼가이샤 | 분지쇄 알킬 헤테로 방향환 유도체 |
| JP5930010B2 (ja) * | 2013-12-13 | 2016-06-08 | 大正製薬株式会社 | ヘテロ芳香環メチル環状アミン誘導体を含有する医薬 |
| JP5907310B2 (ja) * | 2013-12-13 | 2016-04-26 | 大正製薬株式会社 | オキサジナン化合物の結晶形及びその製造方法 |
| EP2915811A1 (en) * | 2014-03-04 | 2015-09-09 | Centre Régional de Lutte contre le Cancer - Centre François Baclesse | MCL-1 modulating compounds for cancer treatment |
| JP6663909B2 (ja) | 2014-08-13 | 2020-03-13 | エオラス セラピューティクス， インコーポレイテッド | オレキシンレセプターモジュレーターとしてのジフルオロピロリジン |
| WO2016100161A1 (en) * | 2014-12-19 | 2016-06-23 | Merck Sharp & Dohme Corp. | Ethyldiamine orexin receptor antagonists |
| WO2016101118A1 (en) * | 2014-12-23 | 2016-06-30 | Merck Sharp & Dohme Corp. | Amidoethyl azole orexin receptor antagonists |
| PT3340971T (pt) * | 2015-08-24 | 2024-06-05 | Zogenix International Ltd | Métodos de tratamento da síndrome de lennox-gastaut com utilização de fenfluramina |
| SG11201804223TA (en) | 2015-11-23 | 2018-06-28 | Sunshine Lake Pharma Co Ltd | OCTAHYDROPYRROLO [3, 4-c] PYRROLE DERIVATIVES AND USES THEREOF |
| SI3414241T1 (sl) | 2016-02-12 | 2022-10-28 | Astrazeneca Ab | Halo-substituitani piperidini kot modulatorji receptorja oreksina |
| PT3426251T (pt) | 2016-03-10 | 2022-07-27 | Janssen Pharmaceutica Nv | Métodos de tratamento da depressão utilizando antagonistas dos recetores de orexina-2 |
| GB201702174D0 (en) | 2017-02-09 | 2017-03-29 | Benevolentai Bio Ltd | Orexin receptor antagonists |
| GB201707499D0 (en) | 2017-05-10 | 2017-06-21 | Benevolentai Bio Ltd | Orexin receptor antagonists |
| GB201707504D0 (en) | 2017-05-10 | 2017-06-21 | Benevolentai Bio Ltd | Orexin receptor antagonists |
| CN109280027A (zh) * | 2018-12-13 | 2019-01-29 | 康化（上海）新药研发有限公司 | 一种5,6-二甲氧基-2-吡啶甲酸的合成方法 |
| CN116600803A (zh) * | 2020-11-02 | 2023-08-15 | 默沙东有限责任公司 | 大环脲食欲素受体激动剂 |
Family Cites Families (161)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3914250A (en) | 1974-08-01 | 1975-10-21 | American Home Prod | 1,4-Diazepino{8 6,5,4-jk{9 carbazoles |
| CA1258454A (en) | 1982-08-10 | 1989-08-15 | Leo Alig | Phenethanolamines |
| IT1159765B (it) | 1982-09-28 | 1987-03-04 | Zanussi A Spa Industrie | Macchina lavabiancheria di tipo modulare |
| MX18467A (es) | 1988-11-23 | 1993-07-01 | Pfizer | Agentes terapeuticos de quinuclidinas |
| US5232929A (en) | 1990-11-28 | 1993-08-03 | Pfizer Inc. | 3-aminopiperidine derivatives and related nitrogen containing heterocycles and pharmaceutical compositions and use |
| US5081122A (en) | 1990-03-05 | 1992-01-14 | Sterling Drug Inc. | Antiglaucoma compositions containing 4-arylcarbonyl-1-(4-morpholinyl)-lower-alkyl)-1H-indoles and method of use thereof |
| US5112820A (en) | 1990-03-05 | 1992-05-12 | Sterling Drug Inc. | Anti-glaucoma compositions containing 2- and 3-aminomethyl-6-arylcarbonyl- or 6-phenylthio-2,3-dihydropyrrolo-(1,2,3-de)-1,4-benzoxazines and method of use thereof |
| US5013837A (en) | 1990-03-08 | 1991-05-07 | Sterling Drug Inc. | 3-Arylcarbonyl-1H-indole-containing compounds |
| US4973587A (en) | 1990-03-08 | 1990-11-27 | Sterling Drug Inc. | 3-arylcarbonyl-1-aminoalkyl-1H-indole-containing antiglaucoma method |
| EP0499313B1 (en) | 1991-02-11 | 1997-06-11 | MERCK SHARP & DOHME LTD. | Azabicyclic compounds, pharmaceutical compositions containing them and their use in therapy |
| DE69200921T2 (de) | 1991-03-01 | 1995-05-04 | Pfizer | 1-azabicyclo[3.2.2]nonan-3-aminderivate. |
| WO1993004040A1 (en) | 1991-08-20 | 1993-03-04 | Merck Sharp & Dohme Limited | Azacyclic compounds, processes for their preparation and pharmaceutical compositions containing them |
| GB9211193D0 (en) | 1992-05-27 | 1992-07-08 | Merck Sharp & Dohme | Therapeutic agents |
| FR2692575B1 (fr) | 1992-06-23 | 1995-06-30 | Sanofi Elf | Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant. |
| US5637699A (en) | 1992-06-29 | 1997-06-10 | Merck & Co., Inc. | Process for preparing morpholine tachykinin receptor antagonists |
| US5387595A (en) | 1992-08-26 | 1995-02-07 | Merck & Co., Inc. | Alicyclic compounds as tachykinin receptor antagonists |
| US5578593A (en) | 1992-12-11 | 1996-11-26 | Merck & Co., Inc. | Spiro piperidines and homologs promote release of growth hormone |
| US5292736A (en) | 1993-02-26 | 1994-03-08 | Sterling Winthrop Inc. | Morpholinoalkylindenes as antiglaucoma agents |
| US5496833A (en) | 1993-04-13 | 1996-03-05 | Merck Sharp & Dohme Limited | Piperidine tachykinin receptor antagonists |
| SK57097A3 (en) | 1994-11-07 | 1998-10-07 | Pfizer | Certain substituted benzylamine derivatives; a new class of neuropeptide y1 specific ligands |
| US5532237A (en) | 1995-02-15 | 1996-07-02 | Merck Frosst Canada, Inc. | Indole derivatives with affinity for the cannabinoid receptor |
| US6194581B1 (en) | 1995-04-07 | 2001-02-27 | Merck & Co., Inc. | Substituted pyridines useful as modulators of acetylcholine receptors |
| US5585388A (en) | 1995-04-07 | 1996-12-17 | Sibia Neurosciences, Inc. | Substituted pyridines useful as modulators of acetylcholine receptors |
| US5831115A (en) | 1995-04-21 | 1998-11-03 | Abbott Laboratories | Inhibitors of squalene synthase and protein farnesyltransferase |
| US5739106A (en) | 1995-06-07 | 1998-04-14 | Rink; Timothy J. | Appetite regulating compositions |
| FR2741621B1 (fr) | 1995-11-23 | 1998-02-13 | Sanofi Sa | Nouveaux derives de pyrazole, procede pour leur preparation et compositions pharmaceutiques en contenant |
| WO1997020821A1 (en) | 1995-12-01 | 1997-06-12 | Novartis Ag | Heteroaryl derivatives |
| WO1997020820A1 (en) | 1995-12-01 | 1997-06-12 | Novartis Ag | Heteroaryl compounds |
| WO1997020822A1 (en) | 1995-12-01 | 1997-06-12 | Novartis Ag | Quinazolin-2,4-diazirines as npy receptor antagonist |
| WO1997019682A1 (en) | 1995-12-01 | 1997-06-05 | Synaptic Pharmaceutical Corporation | Aryl sulfonamide and sulfamide derivatives and uses thereof |
| WO1997020823A2 (en) | 1995-12-01 | 1997-06-12 | Novartis Ag | 2-amino quinazoline derivatives as npy receptor antagonists |
| TW432073B (en) | 1995-12-28 | 2001-05-01 | Pfizer | Pyrazolopyridine compounds |
| AU1856997A (en) | 1996-02-02 | 1997-08-22 | Merck & Co., Inc. | Method for raising hdl cholesterol levels |
| CA2245586A1 (en) | 1996-02-06 | 1997-08-14 | Japan Tobacco Inc. | Novel compounds and pharmaceutical use thereof |
| GB9606805D0 (en) | 1996-03-30 | 1996-06-05 | Glaxo Wellcome Inc | Medicaments |
| CA2273102A1 (en) | 1996-12-03 | 1998-06-11 | Banyu Pharmaceutical Co., Ltd. | Urea derivatives |
| WO1998025907A1 (en) | 1996-12-12 | 1998-06-18 | Banyu Pharmaceutical Co., Ltd. | Pyrazole derivatives |
| WO1998025908A1 (en) | 1996-12-13 | 1998-06-18 | Banyu Pharmaceutical Co., Ltd. | Novel aminopyrazole derivatives |
| AU7738198A (en) | 1996-12-15 | 1998-07-15 | Banyu Pharmaceutical Co., Ltd. | Aminopyrazole derivatives |
| ES2213892T3 (es) | 1997-01-21 | 2004-09-01 | Smithkline Beecham Corporation | Nuevos moduladores del receptor de canabinoides. |
| CN1246845A (zh) | 1997-02-04 | 2000-03-08 | 纳幕尔杜邦公司 | 杀菌的羧酰胺 |
| PT966436E (pt) | 1997-02-21 | 2003-03-31 | Bayer Ag | Arilsulfonamidas e analogos e sua aplicacao para o tratamento de doencas neurodegenerativas |
| WO1998040356A1 (en) | 1997-03-12 | 1998-09-17 | Banyu Pharmaceutical Co., Ltd. | Drugs containing aminopyridine derivatives as the active ingredient |
| US5948777A (en) | 1997-03-18 | 1999-09-07 | Smithkline Beecham Corporation | Cannabinoid receptor agonists |
| FR2761265B1 (fr) | 1997-03-28 | 1999-07-02 | Sanofi Sa | Composition pharmaceutique pour l'administration orale d'un derive du n-piperidino-3-pyrazolecarboxamide, de ses sels et de leurs solvates |
| FR2761266B1 (fr) | 1997-03-28 | 1999-07-02 | Sanofi Sa | Composition pharmaceutique formee par granulation humide pour l'administration orale d'un derive du n-piperidino-3- pyrazolecarboxamide, de ses sels et de leurs solvates |
| AU7079498A (en) | 1997-04-23 | 1998-11-13 | Banyu Pharmaceutical Co., Ltd. | Neuropeptide y receptor antagonist |
| US6001836A (en) | 1997-05-28 | 1999-12-14 | Bristol-Myers Squibb Company | Dihydropyridine NPY antagonists: cyanoguanidine derivatives |
| WO1999002499A1 (en) | 1997-07-11 | 1999-01-21 | Japan Tobacco Inc. | Quinoline compounds and medicinal uses thereof |
| AU9185598A (en) | 1997-09-25 | 1999-04-12 | Banyu Pharmaceutical Co., Ltd. | Novel neuropeptide y receptor antagonists |
| US6362009B1 (en) | 1997-11-21 | 2002-03-26 | Merck & Co., Inc. | Solid phase synthesis of heterocycles |
| WO1999027965A1 (en) | 1997-11-28 | 1999-06-10 | Banyu Pharmaceutical Co., Ltd. | Antihyperlipemic agents |
| US6174901B1 (en) | 1998-12-18 | 2001-01-16 | Amgen Inc. | Substituted pyridine and pyridazine compounds and methods of use |
| EP1068207A1 (en) | 1998-04-02 | 2001-01-17 | Neurogen Corporation | AMINOALKYL SUBSTITUTED 9H-PYRIDINO 2,3-b]INDOLE AND 9H-PYRIMIDINO 4,5-b]INDOLE DERIVATIVES |
| ES2223170T3 (es) | 1998-04-29 | 2005-02-16 | Ortho-Mcneil Pharmaceutical, Inc. | Aminotetralinas n sustituidas, ligandos del receptor y y5 del neuropeptido que sirve para el tratamiento de la obesidad y otros trastornos. |
| US6329395B1 (en) | 1998-06-08 | 2001-12-11 | Schering Corporation | Neuropeptide Y5 receptor antagonists |
| HN1998000027A (es) | 1998-08-19 | 1999-06-02 | Bayer Ip Gmbh | Arilsulfonamidas y analagos |
| DE19837627A1 (de) | 1998-08-19 | 2000-02-24 | Bayer Ag | Neue Aminosäureester von Arylsulfonamiden und Analoga |
| US6358951B1 (en) | 1998-08-21 | 2002-03-19 | Pfizer Inc. | Growth hormone secretagogues |
| US6337332B1 (en) | 1998-09-17 | 2002-01-08 | Pfizer Inc. | Neuropeptide Y receptor antagonists |
| DE69929235T2 (de) | 1998-11-10 | 2006-08-24 | Merck & Co., Inc. | Spiro-indole als y5-rezeptor antagonisten |
| BR0008494A (pt) * | 1999-02-24 | 2002-02-05 | Hoffmann La Roche | Derivados de 3-fenilpiridina e seu uso como antagonista do receptor de nk-1 |
| US6340683B1 (en) | 1999-04-22 | 2002-01-22 | Synaptic Pharmaceutical Corporation | Selective NPY (Y5) antagonists (triazines) |
| WO2000064880A1 (en) | 1999-04-22 | 2000-11-02 | Synaptic Pharmaceutical Corporation | Selective npy (y5) antagonists |
| HK1041263A1 (zh) | 1999-05-05 | 2002-07-05 | Ortho-Mcneil Pharmaceutical, Inc. | 可用於治疗肥胖和其他疾病的3a，4，5，9b-四氢-1h-苯并[e]吲-2-基胺衍生的神经肽y受体配体 |
| EP1177188B1 (en) | 1999-05-12 | 2005-10-12 | Ortho-McNeil Pharmaceutical, Inc. | Pyrazole carboxamides useful for the treatment of obesity and other disorders |
| DK1194421T3 (da) | 1999-06-30 | 2006-02-13 | Lundbeck & Co As H | Selektive NPY (Y5) antagonister |
| AU6000900A (en) | 1999-07-23 | 2001-02-13 | Astrazeneca Uk Limited | Carbazole derivatives and their use as neuropeptide y5 receptor ligands |
| EP1202986B1 (en) | 1999-07-28 | 2005-10-12 | Ortho-McNeil Pharmaceutical, Inc. | Amine and amide derivatives as ligands for the neuropeptide y y5 receptor useful in the treatment of obesity and other disorders |
| TWI279402B (en) | 1999-08-20 | 2007-04-21 | Banyu Pharma Co Ltd | Spiro compounds having NPY antagonistic activities and agents containing the same |
| US6462053B1 (en) | 1999-08-20 | 2002-10-08 | Banyu Pharmaceutical Co., Ltd. | Spiro compounds |
| AU7315800A (en) | 1999-09-20 | 2001-04-24 | Takeda Chemical Industries Ltd. | Mch antagonists |
| WO2001021577A2 (en) | 1999-09-20 | 2001-03-29 | Takeda Chemical Industries, Ltd. | Melanin concentrating hormone antagonist |
| US6414002B1 (en) | 1999-09-22 | 2002-07-02 | Bristol-Myers Squibb Company | Substituted acid derivatives useful as antidiabetic and antiobesity agents and method |
| CN1377355A (zh) | 1999-09-30 | 2002-10-30 | 纽罗杰有限公司 | 氨基取代的吡唑并[1,5－a]－1,5－嘧啶和吡唑并[1,5－a]－1,3,5－三嗪 |
| AU7738100A (en) | 1999-09-30 | 2001-04-30 | Neurogen Corporation | Certain alkylene diamine-substituted pyrazolo(1,5,-a)-1,5-pyrimidines and pyrazolo(1,5-a)-1,3,5-triazines |
| CZ20021086A3 (cs) | 1999-09-30 | 2002-10-16 | Neurogen Corporation | Alkylendiaminem substituované heterocykly |
| JP4180276B2 (ja) | 1999-12-16 | 2008-11-12 | シェーリング コーポレイション | 置換イミダゾール神経ペプチドｙｙ５レセプタアンタゴニスト |
| WO2001056592A1 (en) | 2000-02-01 | 2001-08-09 | Novo Nordisk A/S | Use of compounds for the regulation of food intake |
| US6653304B2 (en) | 2000-02-11 | 2003-11-25 | Bristol-Myers Squibb Co. | Cannabinoid receptor modulators, their processes of preparation, and use of cannabinoid receptor modulators for treating respiratory and non-respiratory diseases |
| AU3412801A (en) | 2000-02-22 | 2001-09-03 | Banyu Pharma Co Ltd | Novel imidazoline compounds |
| US6531478B2 (en) | 2000-02-24 | 2003-03-11 | Cheryl P. Kordik | Amino pyrazole derivatives useful for the treatment of obesity and other disorders |
| FR2805817B1 (fr) | 2000-03-03 | 2002-04-26 | Aventis Pharma Sa | Compositions pharmaceutiques contenant des derives d'azetidine, les nouveaux derives d'azetidine et leur preparation |
| FR2805810B1 (fr) | 2000-03-03 | 2002-04-26 | Aventis Pharma Sa | Compositions pharmaceutiques contenant des derives de 3- amino-azetidine, les nouveaux derives et leur preparation |
| FR2805818B1 (fr) | 2000-03-03 | 2002-04-26 | Aventis Pharma Sa | Derives d'azetidine, leur preparation et les compositions pharmaceutiques les contenant |
| EP1132389A1 (en) | 2000-03-06 | 2001-09-12 | Vernalis Research Limited | New aza-indolyl derivatives for the treatment of obesity |
| EP1142886A1 (en) | 2000-04-07 | 2001-10-10 | Aventis Pharma Deutschland GmbH | Percyquinnin, a process for its production and its use as a pharmaceutical |
| EP1285651B1 (en) | 2000-04-28 | 2010-09-01 | Takeda Pharmaceutical Company Limited | Melanin concentrating hormone antagonists |
| GB0010757D0 (en) | 2000-05-05 | 2000-06-28 | Astrazeneca Ab | Chemical compounds |
| GB0011013D0 (en) | 2000-05-09 | 2000-06-28 | Astrazeneca Ab | Chemical compounds |
| US6444675B2 (en) | 2000-05-10 | 2002-09-03 | Bristol-Myers Squibb Company | 4-alkyl and 4-cycloalkyl derivatives of dihydropyridine NPY antagonists |
| US6432960B2 (en) | 2000-05-10 | 2002-08-13 | Bristol-Myers Squibb Company | Squarate derivatives of dihydropyridine NPY antagonists |
| US6479482B2 (en) | 2000-05-10 | 2002-11-12 | Bristol-Myers Squibb Company | Alkylamine derivatives of dihydropyridine NPY antagonists |
| JP2004507456A (ja) | 2000-05-11 | 2004-03-11 | ブリストル−マイヤーズ スクイブ カンパニー | 成長ホルモン分泌促進薬として有用なテトラヒドロイソキノリン類縁体 |
| AU2001256733A1 (en) | 2000-05-16 | 2001-11-26 | Takeda Chemical Industries Ltd. | Melanin-concentrating hormone antagonist |
| EP1286697A2 (en) | 2000-05-17 | 2003-03-05 | Eli Lilly And Company | Method for selectively inhibiting ghrelin action |
| US6391881B2 (en) | 2000-05-19 | 2002-05-21 | Bristol-Myers Squibb Company | Thiourea derivatives of dihydropyridine NPY antagonists |
| SE0001899D0 (sv) | 2000-05-22 | 2000-05-22 | Pharmacia & Upjohn Ab | New compounds |
| WO2002006245A1 (en) | 2000-07-05 | 2002-01-24 | Synaptic Pharmarceutical Corporation | Selective melanin concentrating hormone-1 (mch1) receptor antagonists and uses thereof |
| AU2001279294A1 (en) | 2000-07-06 | 2002-01-21 | Neurogen Corporation | Melanin concentrating hormone receptor ligands |
| CN1443198A (zh) | 2000-07-24 | 2003-09-17 | 阿达纳生物科学有限公司 | Ghrelin拮抗剂 |
| EP1325008B1 (en) | 2000-07-31 | 2005-10-05 | F. Hoffmann-La Roche Ag | Piperazine derivatives |
| JP2004509108A (ja) | 2000-09-14 | 2004-03-25 | シェーリング コーポレイション | 置換尿素神経ペプチドｙｙ５受容体アンタゴニスト |
| BR0114630A (pt) | 2000-10-13 | 2003-07-01 | Lilly Co Eli | Secretagogos de hormÈnio do crescimento |
| ES2311563T3 (es) | 2000-10-16 | 2009-02-16 | F. Hoffmann-La Roche Ag | Derivados de indolina y su utilizacion como ligandos del receptor de 5-ht2. |
| WO2002036596A2 (en) | 2000-11-03 | 2002-05-10 | Wyeth | CYCLOALKYL[b][1,4]DIAZEPINO[6,7,1-hi]INDOLES AND DERIVATIVES |
| PL361690A1 (en) | 2000-11-20 | 2004-10-04 | Biovitrum Ab | Piperazinylpyrazine compounds as agonist or antagonist of serotonin 5ht-2 receptor |
| CA2449899C (en) | 2000-11-20 | 2010-04-06 | Biovitrum Ab | Piperazinylpyrazines compounds as antagonists of serotonin 5-ht2 receptor |
| MXPA03004245A (es) | 2000-12-12 | 2003-09-22 | Neurogen Corp | Espiro[isobenzofuran-1,4'piperidin]-3-onas y 3h-espiroisobenzofuran-1,4'-piperidinas. |
| GB0030710D0 (en) | 2000-12-15 | 2001-01-31 | Hoffmann La Roche | Piperazine derivatives |
| CN1482912A (zh) | 2000-12-21 | 2004-03-17 | ���鹫˾ | 杂芳基脲神经肽yy5受体拮抗剂 |
| HK1054390B (en) | 2000-12-22 | 2006-01-06 | Schering Corporation | Piperidine mch antagonists and their use in the treatment of obesity |
| ATE369368T1 (de) | 2000-12-27 | 2007-08-15 | Hoffmann La Roche | Indolderivate und deren verwendung als 5-ht2b- und 5-ht2c-rezeptorliganden |
| BR0206831A (pt) | 2001-02-02 | 2004-07-06 | Takeda Chemical Industries Ltd | Composto, cristal, agente farmacêutico, agentes para profilaxia ou tratamento de diabetes, de complicações diabéticas, de tolerância prejudicada à glucose e de obesidade, inibidor de peptidase, uso de um composto, e, método de produção de um composto |
| US6900329B2 (en) | 2001-03-21 | 2005-05-31 | Schering Corporation | MCH antagonists and their use in the treatment of obesity |
| IL157456A0 (en) | 2001-03-21 | 2004-03-28 | Pharmacopeia Inc Pharmacopeia | Aryl and biaryl compounds having mch modulatory activity |
| KR100846614B1 (ko) | 2001-03-22 | 2008-07-16 | 솔베이 파마슈티칼스 비. 브이 | Ｃｂ1-길항 활성을 갖는 4,5-디하이드로-1ｈ-피라졸 유도체 |
| US6573287B2 (en) | 2001-04-12 | 2003-06-03 | Bristo-Myers Squibb Company | 2,1-oxazoline and 1,2-pyrazoline-based inhibitors of dipeptidyl peptidase IV and method |
| ATE460163T1 (de) | 2001-04-12 | 2010-03-15 | Pharmacopeia Llc | Arly und diaryl piperidinderivate verwendbar als mch-hemmer |
| FR2824825B1 (fr) | 2001-05-15 | 2005-05-06 | Servier Lab | Nouveaux derives d'alpha-amino-acides, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| BR0209932A (pt) | 2001-05-22 | 2004-10-13 | Neurogen Corp | Composto ou sal farmaceuticamente aceitável do mesmo, composição farmacêutica, preparação farmacêutica embalada, métodos para modular ligação de mch a um receptor de mch e de mvc, para alterar a atividade de transdução de sinal de um receptor de mch em uma célula, para tratar uma doença ou distúrbio associado com a ativação de receptor de mch patogênico obesidade e para determinar a presença ou ausência de receptor de mch em uma amostra, e, uso de um composto |
| WO2002094825A1 (en) | 2001-05-22 | 2002-11-28 | Banyu Pharmaceutical Co., Ltd. | Novel spiropiperidine derivative |
| US7098239B2 (en) | 2001-06-20 | 2006-08-29 | Merck & Co., Inc | Dipeptidyl peptidase inhibitors for the treatment of diabetes |
| CA2450475A1 (en) | 2001-06-20 | 2003-01-03 | Linda Brockunier | Dipeptidyl peptidase inhibitors for the treatment of diabetes |
| GB0115517D0 (en) | 2001-06-25 | 2001-08-15 | Ferring Bv | Novel antidiabetic agents |
| US7183290B2 (en) | 2001-06-27 | 2007-02-27 | Smithkline Beecham Corporation | Fluoropyrrolidines as dipeptidyl peptidase inhibitors |
| US7196201B2 (en) | 2001-06-27 | 2007-03-27 | Smithkline Beecham Corporation | Pyrrolidines as dipeptidyl peptidase inhibitors |
| CA2419888A1 (en) | 2001-06-27 | 2003-01-09 | Probiodrug Ag | Peptide structures useful for competitive modulation of dipeptidyl peptidase iv catalysis |
| DE60222667T2 (de) | 2001-06-27 | 2008-07-17 | Smithkline Beecham Corp. | Fluorpyrrolidine als dipeptidylpeptidaseinhibitoren |
| DE60225556D1 (de) | 2001-07-03 | 2008-04-24 | Novo Nordisk As | Dpp-iv-inhibierende purin-derivative zur behandlung von diabetes |
| EA005934B1 (ru) | 2001-07-05 | 2005-08-25 | Х. Лундбекк А/С | Замещённые анилиновые пиперидины в качестве селективных антагонистов мсн |
| UA74912C2 (en) | 2001-07-06 | 2006-02-15 | Merck & Co Inc | Beta-aminotetrahydroimidazo-(1,2-a)-pyrazines and tetratriazolo-(4,3-a)-pyrazines as inhibitors of dipeptylpeptidase for the treatment or prevention of diabetes |
| AU2002319627A1 (en) | 2001-07-20 | 2003-03-03 | Merck And Co., Inc. | Substituted imidazoles as cannabinoid receptor modulators |
| BRPI0104510B8 (pt) | 2001-07-27 | 2021-05-25 | Embrapa Pesquisa Agropecuaria | peptídeos antibióticos da família das phylloseptinas isolados da secreção da pele de phylloseptina hypocondrialis e composição antimicrobiana relacionada |
| PL367983A1 (en) | 2001-08-07 | 2005-03-21 | Banyu Pharmaceutical Co, Ltd. | Spiro compounds |
| GB0126292D0 (en) | 2001-11-01 | 2002-01-02 | Smithkline Beecham Plc | Compounds |
| GB0130341D0 (en) | 2001-12-19 | 2002-02-06 | Smithkline Beecham Plc | Compounds |
| JP2005320249A (ja) | 2002-05-01 | 2005-11-17 | Banyu Pharmaceut Co Ltd | ２−アミノピラジン誘導体の製造方法 |
| AR040241A1 (es) | 2002-06-10 | 2005-03-23 | Merck & Co Inc | Inhibidores de la 11-beta-hidroxiesteroide deshidrogrenasa 1 para el tratamiento de la diabetes obesidad y dislipidemia |
| US7105526B2 (en) | 2002-06-28 | 2006-09-12 | Banyu Pharmaceuticals Co., Ltd. | Benzimidazole derivatives |
| US6869966B2 (en) | 2002-09-30 | 2005-03-22 | Banyu Pharmaceutical Co., Ltd. | N-substituted-2-oxodihydropyridine derivatives |
| US20040116479A1 (en) | 2002-10-04 | 2004-06-17 | Fortuna Haviv | Method of inhibiting angiogenesis |
| MY134457A (en) | 2002-11-22 | 2007-12-31 | Merck & Co Inc | Substituted amides |
| JO2397B1 (en) | 2002-12-20 | 2007-06-17 | ميرك شارب اند دوم كوربوريشن | Terazol derivatives as beta-hydroxy steroid dihydrogenase-1 inhibitors |
| CN1802351A (zh) | 2003-06-11 | 2006-07-12 | 麦克公司 | 被取代的3－烷基和3－链烯基氮杂环丁烷衍生物 |
| EP1669348A4 (en) | 2003-09-30 | 2009-03-11 | Eisai R&D Man Co Ltd | NEW ANTIPILIC AGENT CONTAINING A HETEROCYCLIC COMPOUND |
| HUP0400405A3 (en) | 2004-02-10 | 2009-03-30 | Sanofi Synthelabo | Pyrimidine derivatives, process for producing them, their use, pharmaceutical compositions containing them and their intermediates |
| CN1933838A (zh) | 2004-02-12 | 2007-03-21 | 默克公司 | 作为代谢型谷氨酸受体－5调节剂的联吡啶酰胺 |
| AU2006228683B2 (en) | 2005-04-01 | 2012-02-02 | Vfp Therapies | New heterocyclic compounds, their preparation and their use as medicaments, in particular as anti-Alzheimer agents |
| JP2008538361A (ja) | 2005-04-12 | 2008-10-23 | メルク エンド カムパニー インコーポレーテッド | アミドプロポキシフェニルオレキシン受容体アンタゴニスト |
| WO2007011760A2 (en) | 2005-07-15 | 2007-01-25 | Kalypsys, Inc. | Inhibitors of mitotic kinesin |
| US20090088452A1 (en) | 2005-11-22 | 2009-04-02 | Coleman Paul J | Indole Orexin Receptor Antagonists |
| US20080214301A1 (en) | 2007-03-02 | 2008-09-04 | Wildtangent, Inc. | In-game advertisements |
| AU2008223066A1 (en) | 2007-03-02 | 2008-09-12 | Northwestern University | Compositions comprising derivatives of 3 -phenylpyridazine for treating seizure-related disorders |
| EP2131654A4 (en) | 2007-03-02 | 2011-02-02 | Merck Sharp & Dohme | Bipyridine-carboxamide-orexin receptor Antagonist |
| BRPI0814758A2 (pt) | 2007-08-03 | 2015-03-03 | Hoffmann La Roche | Piridinacarboxamida e derivados de benzamida como ligantes taar1 |
| WO2009020642A1 (en) * | 2007-08-09 | 2009-02-12 | Merck & Co., Inc. | Pyridine carboxamide orexin receptor antagonists |
| AR072899A1 (es) | 2008-08-07 | 2010-09-29 | Merck Sharp & Dohme | Derivados de terpiridina-carboxamida antagonistas de receptores de orexina, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento del insomnio y la obesidad. |
| US8399494B2 (en) | 2008-10-30 | 2013-03-19 | Merck Sharp & Dohme Corp. | 2,5-disubstituted phenyl carboxamide orexin receptor antagonists |
| US8703770B2 (en) * | 2008-10-30 | 2014-04-22 | Merck Sharp & Dohme Corp. | Pyridazine carboxamide orexin receptor antagonists |
| US20120065205A1 (en) | 2009-06-01 | 2012-03-15 | Mercer Swati P | Pyrazine carboxamide orexin receptor antagonists |
-
2009
- 2009-10-26 EP EP09741173.0A patent/EP2350010B1/en active Active
- 2009-10-26 JP JP2011534650A patent/JP5635991B2/ja not_active Expired - Fee Related
- 2009-10-26 AU AU2009308980A patent/AU2009308980B2/en not_active Ceased
- 2009-10-26 CA CA2741644A patent/CA2741644C/en not_active Expired - Fee Related
- 2009-10-26 NZ NZ592544A patent/NZ592544A/xx not_active IP Right Cessation
- 2009-10-26 CN CN200980153418.3A patent/CN102272103B/zh not_active Expired - Fee Related
- 2009-10-26 US US13/124,568 patent/US8592457B2/en active Active
- 2009-10-26 BR BRPI0919876A patent/BRPI0919876A8/pt not_active IP Right Cessation
- 2009-10-26 MX MX2011004551A patent/MX2011004551A/es active IP Right Grant
- 2009-10-26 KR KR1020117009859A patent/KR101320245B1/ko not_active Expired - Fee Related
- 2009-10-26 PE PE2011000959A patent/PE20110852A1/es not_active Application Discontinuation
- 2009-10-26 EA EA201170624A patent/EA201170624A1/ru unknown
- 2009-10-26 WO PCT/US2009/061987 patent/WO2010051236A1/en not_active Ceased
-
2011
- 2011-04-12 TN TN2011000171A patent/TN2011000171A1/fr unknown
- 2011-04-17 IL IL212436A patent/IL212436A0/en unknown
- 2011-04-29 NI NI201100084A patent/NI201100084A/es unknown
- 2011-04-29 DO DO2011000120A patent/DOP2011000120A/es unknown
- 2011-04-29 ZA ZA2011/03156A patent/ZA201103156B/en unknown
- 2011-04-29 EC EC2011011019A patent/ECSP11011019A/es unknown
- 2011-04-29 CR CR20110228A patent/CR20110228A/es unknown
- 2011-04-29 CL CL2011000976A patent/CL2011000976A1/es unknown
- 2011-05-12 CO CO11058578A patent/CO6361994A2/es not_active Application Discontinuation
- 2011-05-19 MA MA33859A patent/MA32804B1/fr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2009308980B2 (en) | 2013-02-28 |
| ECSP11011019A (es) | 2011-05-31 |
| CO6361994A2 (es) | 2012-01-20 |
| MX2011004551A (es) | 2011-05-25 |
| CR20110228A (es) | 2011-06-24 |
| CN102272103A (zh) | 2011-12-07 |
| BRPI0919876A2 (pt) | 2015-08-18 |
| US8592457B2 (en) | 2013-11-26 |
| ZA201103156B (en) | 2012-01-25 |
| TN2011000171A1 (en) | 2012-12-17 |
| JP2012507538A (ja) | 2012-03-29 |
| KR20110071101A (ko) | 2011-06-28 |
| EP2350010A1 (en) | 2011-08-03 |
| JP5635991B2 (ja) | 2014-12-03 |
| CL2011000976A1 (es) | 2012-02-24 |
| DOP2011000120A (es) | 2011-10-15 |
| MA32804B1 (fr) | 2011-11-01 |
| CA2741644A1 (en) | 2010-05-06 |
| AU2009308980A1 (en) | 2010-05-06 |
| PE20110852A1 (es) | 2011-11-25 |
| EP2350010B1 (en) | 2014-03-26 |
| KR101320245B1 (ko) | 2013-10-30 |
| IL212436A0 (en) | 2011-06-30 |
| CN102272103B (zh) | 2015-10-21 |
| NZ592544A (en) | 2013-01-25 |
| EA201170624A1 (ru) | 2011-12-30 |
| NI201100084A (es) | 2011-11-03 |
| US20110201591A1 (en) | 2011-08-18 |
| CA2741644C (en) | 2013-05-07 |
| WO2010051236A1 (en) | 2010-05-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0919876A8 (pt) | Composto, composição farmacêutica, uso de um composto, e, método para intensificar a qualidade do sono, para tratar insônia, e para tratar ou controlar obesidade em um paciente mamífero que necessita do mesmo. | |
| BRPI0811842A2 (pt) | Composto, composição farmacêutica, uso de um composto, e, métodos para aumentar a qualidade do sono em um paciente mamífero, para tratar a insônia em um paciente mamífero, e para tratar ou controlar a obesidade em um paciente mamífero | |
| BRPI0719361B8 (pt) | composto, composição farmacêutica, e, uso do composto | |
| BR112014009486A2 (pt) | composto, composição farmacêutica, uso de um composto, e, métodos para intensificar a qualidade do sono, para tratamento de insônia e para tratamento ou controle da obesidade | |
| BR112012014180A2 (pt) | composto, composição farmacêutica, uso da composição farmacêutica, e, método para tratar uma doença ou em distúrbio. | |
| DK2049529T3 (da) | Substituerede diazepan-orexin-receptor- antagonister | |
| BRPI0916235A8 (pt) | Composto, composição farmacêutica, e, uso do composto ou da composição | |
| MA32898B1 (fr) | Modulateurs allosteriques positifs du recepteur m1 d'arylmethylbenzoquinazolinone | |
| EA201171197A8 (ru) | Замещенные производные азоантрацена, фармацевтические композиции и способы их применения | |
| PA8780201A1 (es) | Derivados de pirasol sustituidos con heteroaril utiles para tratar trastornos hiperproliferativos y enfermedades asociadas con angiogénesis | |
| UA106873C2 (uk) | Сполуки заміщених діазепанів як антагоністи орексинових рецепторів | |
| TW200800958A (en) | N-substituted-azacyclylamines as histamine-3 antagonists | |
| MX2010002899A (es) | Derivados de azaciclilisoquinolinona e isoindolinona como antagonistas de la histamina-3. | |
| MY147677A (en) | Piperazinyl derivatives useful in the treatment of gpr38 receptor mediated diseases | |
| ATE542795T1 (de) | Benzylpiperazinderivate als motilin- rezeptorantagonisten | |
| BRPI0911678B8 (pt) | maleato de orvepitant cristalino anidro, composição farmacêutica compreedendo o dito maleato e uso do mesmo para o tratamento ou profilaxia de doenças do sistema nervoso central | |
| BR112012014235A2 (pt) | tiazóis bicíclicos como moduladores alostéricos de receptores mglur5 | |
| ATE552257T1 (de) | Positive allosterische chinolizidinon-m1- rezeptormodulatoren | |
| BR112014001714A2 (pt) | derivados de carboxamida e ureia aromáticos bicíclicos substituídos como ligantes de receptor vaniloide | |
| ATE455111T1 (de) | Einen azepin-kern enthaltende antagonisten des histaminrezeptors | |
| BR112014011262A2 (pt) | carboxamida com base em pirazolila substituída e derivados de ureia que portam uma porção de fenila substituída com um grupo contendo o como ligantes de receptor vaniloide | |
| ATE525370T1 (de) | Phthalazin- und pyridoä3,4- düpyridazinverbindungen als h1-rezeptor- antagonisten | |
| BR112012014436A2 (pt) | tiazóis bicíclicos como moduladores alostéricos de receptores mglur5 | |
| BR112014011108A2 (pt) | derivados de carboxamida e ureia à base de pirazolila substituída portando uma porção fenila substituída com um grupo contendo so2 como ligantes do receptor de vaniloides | |
| CL2008000497A1 (es) | Compuestos derivados de ciclohexil-amida del acido aril-carboxilico, antagonistas del receptor de quimiocina 2 y 5; proceso de preparacion de dichos compuestos; composicion farmaceutica; y uso del compuesto para el tratamiento de una enfermedad o con |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B25A | Requested transfer of rights approved |
Owner name: SCHERING CORPORATION (UY) |
|
| B25D | Requested change of name of applicant approved |
Owner name: MERCK SHARP AND DOHME CORP. (US) |
|
| B25G | Requested change of headquarter approved |
Owner name: MERCK SHARP AND DOHME CORP. (US) |
|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] | ||
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |